Healthcare / Medical Instruments & SuppliesKOSDAQ
$4895.00
-795.00 (-13.97%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 15%
FCF escenarios
weak_data · normalized FCF $-4.8B · quality 30.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$175.5B
P/E
N/A
•EV/EBITDA
25.2x
↑ROE
-10.1%
↓Gross Margin
47.9%
↓Debt/Equity
1.79
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+18.7%
FCF CAGR
—
FCF margin
-6.2%
FCF / Net income
0.73x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $76.90B · net income $-6.60B · FCF $-4.80B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $76.90B | $76.90B | $68.52B | $58.72B | $45.99B |
| Net Income | $-6.60B | $-6.60B | $-188.3M | $13.97B | $1.46B |
| EBITDA | $11.45B | $11.45B | $15.48B | $22.31B | $16.58B |
| EPS | -184.00 | -184.00 | -2.50 | 67.50 | 40.50 |
| Gross Margin | 47.9% | 47.9% | 48.8% | 48.2% | 48.5% |
| Operating Margin | 5.0% | 5.0% | 6.0% | 4.5% | 8.7% |
| Net Margin | -8.6% | -8.6% | -0.3% | 23.8% | 3.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.79 | 1.79 | 1.64 | 1.70 | 1.89 |
| Current Ratio | 0.43 | 0.43 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.80B | $-4.80B | $-5.08B | $-327.7M | $-49.82B |
| Returns | |||||
| ROE | -10.1% | -10.1% | -0.3% | 19.5% | 2.6% |
| Valuation | |||||
| P/E | — | — | — | 115.70 | 173.46 |
| EV/EBITDA | 25.15 | 25.15 | 42.83 | 16.97 | 20.44 |
| P/B | 2.68 | 2.68 | 7.85 | 4.24 | 4.43 |
| Growth & Yield | |||||
| Revenue Growth | 12.2% | 12.2% | 16.7% | 27.7% | — |
| EPS Growth | -7260.0% | -7260.0% | -103.7% | 66.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.50 → -184.00
Residual
-29.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.